If You Invested in Tourmaline Bio (TRML)

Tourmaline Bio, Inc. (NASDAQ: TRML) is described in its public communications as a late-stage clinical biotechnology company focused on developing medicines for patients with life-altering immune and inflammatory diseases. The company’s work centers on inflammation biology and immune-mediated conditions, with the goal of establishing new standards of care in areas of high unmet medical need.

According to multiple company press releases, Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006), a long-acting, fully human, anti-IL-6 monoclonal antibody. Pacibekitug is described as having a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. The company highlights pacibekitug’s potential to address diseases driven by IL-6–mediated inflammation.

Therapeutic focus and development programs

Tourmaline states that it is initially developing pacibekitug in atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED) as its first two indications. Company disclosures further note plans to expand development into abdominal aortic aneurysm (AAA) and additional diseases in the future. Across its communications, Tourmaline emphasizes a focus on cardiovascular inflammation and immune and inflammatory diseases that significantly affect patients’ lives.

The company reports that pacibekitug has been studied in approximately 450 participants, including patients with autoimmune disorders, across six completed clinical trials, excluding ongoing trials. This prior clinical experience underpins the current late-stage development strategy outlined in Tourmaline’s news releases.

Pacibekitug and cardiovascular inflammation

A central element of Tourmaline’s program is the Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein (hs-CRP) and chronic kidney disease. Company announcements describe TRANQUILITY as a multicenter, randomized, double-blind, placebo-controlled trial evaluating quarterly and monthly subcutaneous dosing of pacibekitug. The primary endpoint is the median time-averaged percent change in hs-CRP through Day 90, with key secondary and responder endpoints also focused on hs-CRP.

Tourmaline has reported positive topline results from TRANQUILITY, including rapid, deep, and durable reductions in hs-CRP through Day 90 across all pacibekitug arms, with high statistical significance compared with placebo. The company further notes that, based on these data, pacibekitug is the first IL-6 inhibitor known to demonstrate deep hs-CRP reductions with quarterly dosing in a clinical trial setting. In addition, Tourmaline has highlighted pharmacodynamic findings such as reductions in biomarkers associated with IL-6 pathway activity, including lipoprotein(a), fibrinogen, and serum amyloid A.

In its public updates, Tourmaline links these TRANQUILITY results to a broader cardiovascular inflammation strategy, including planning for a potential Phase 3 cardiovascular outcomes trial in ASCVD and a Phase 2 proof-of-concept trial in AAA. The company also references scientific work and advisory input around IL-6 inhibition and residual inflammatory risk in cardiovascular disease.

Thyroid eye disease and additional indications

Beyond cardiovascular inflammation, Tourmaline is running the Phase 2b spiriTED trial in thyroid eye disease (TED). Company communications describe spiriTED as ongoing, with topline data expected after completion of the trial. Tourmaline has indicated that it plans to provide additional information on future development plans in TED following review of the Phase 2b data.

In multiple press releases, Tourmaline also notes plans to expand pacibekitug development into AAA and other diseases after the cardiovascular and TED programs reach key milestones. These statements position pacibekitug as a potential platform asset for a range of IL-6–driven inflammatory and immune conditions, as described by the company.

Corporate developments and acquisition by Novartis

Tourmaline has reported that it is headquartered in New York, New York, and that its common stock, with a par value of $0.0001 per share, traded on the Nasdaq Global Select Market under the symbol TRML prior to a change in control. In a press release and related SEC filings, Tourmaline and Novartis AG announced an Agreement and Plan of Merger under which a Novartis subsidiary would commence a cash tender offer to acquire all outstanding shares of Tourmaline.

According to an October 28, 2025 Form 8-K, a tender offer at $48.00 per share in cash was completed, and a subsequent merger under Delaware law was effected. As described in that filing, Purchaser, an indirect wholly owned subsidiary of Novartis, merged with and into Tourmaline, with Tourmaline surviving as an indirect wholly owned subsidiary of Novartis. The same filing notes that, in connection with the merger, Tourmaline requested that the Nasdaq Global Select Market suspend trading in its shares, remove them from listing, and file a Form 25 to report the delisting. The company also indicated its intention to file a Form 15 to deregister the shares and suspend its reporting obligations under the Exchange Act.

Following the effective time of the merger, the Form 8-K states that holders of Tourmaline common stock (other than specified excluded shares) ceased to have rights as stockholders, other than the right to receive the merger consideration. The filing further notes that Tourmaline became an indirect wholly owned subsidiary of Novartis and that a change in control occurred.

Scientific and advisory focus

Tourmaline’s public updates highlight the role of IL-6–driven inflammation in cardiovascular disease and TED. The company has described building a Cardiovascular Scientific Advisory Board, including recognized experts in cardiovascular disease and inflammation, to provide strategic guidance on the development of pacibekitug. Company communications reference scientific publications and conference presentations related to IL-6 signaling, cardiovascular inflammation, AAA, and TED, reflecting an emphasis on genetics, biomarkers such as hs-CRP, and clinical trial design in these indications.

Investment profile and company status

Prior to its acquisition, Tourmaline communicated that it was an emerging growth company and a late-stage clinical biotechnology issuer with ongoing Phase 2 programs and preparations for potential later-stage trials. With the completion of the tender offer and merger described in the October 28, 2025 Form 8-K, Tourmaline’s shares were delisted from Nasdaq, and the company became a private, indirect wholly owned subsidiary of Novartis. For investors and researchers, TRML now represents the historical public ticker for Tourmaline Bio, Inc. before its acquisition and delisting.